UC Investments
UC Investments is the Office of the Chief Investment Officer of the Regents of the University of California, managing approximately $190 billion in retirement, endowment, and working capital assets on behalf of the university system's students, faculty, staff, retirees, 10 campuses, and six academic health centers.
33% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $257.7M (across 13 rounds with reported amounts).
Portfolio
12
Fund Size
—
Top Stage
Series A
Last 12 Mo
4
Team
Ananthaswamy, Satish
Senior Managing Director
Sterman, Steven
Senior Managing Director
Huie, Craig
Managing Director
Merz, Marco
Managing Director
Adkison, Larry
Director
Castro, Jim
Director, Investment Transaction Services
Klein, Dianne
Investment Director
Lo, Tony
Director
Lyons, Bradley
Director
Ong, Byron
Director
Pulling, Wendy
Director of ESG Integration
Staines, Aaron
Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
Portfolio
| Company | Round | Amount | Date |
|---|---|---|---|
 Unrivaled | Series C | $100M | Aug 2026 |
 Qolab | Series B | $54.2M | Jul 2026 |
 Prenosis | Series A | $20M | Jan 2026 |
 LMArena | Series C | $150M | Jan 2026 |
| LMArena | Series A | $150M | Jan 2026 |
| LMArena | Seed | $100M | May 2025 |
 Neurona Therapeutics | Unknown | $102M | Apr 2025 |
 Eikon Therapeutics, Inc. | Series D | $350.7M | Feb 2025 |
 Neurona | Series A | $102M | Jan 2025 |
 Bright Uro | Series A | $32M | Oct 2024 |
 Digestiva | Series A | — | Jul 2024 |
 Eikon | Series B | — | Jan 2022 |
 Databricks | Series H | $1.6B | Aug 2021 |
 A2 Biotherapeutics | Series B | $71.5M | Oct 2020 |
| Eikon Therapeutics, Inc. | Series B | $517.8M | — |
Top Co-Investors
Last updated: 7 October 2026